Muscle wasting is the most important phenotypic and clinical feature of cancer cachexia, and the principal cause of impaired physical function, fatigue, and respiratory complications. Muscle loss has been attributed to a variable combination of reduced nutritional intake and an imbalance between anabolic and catabolic processes. It has been suggested that defective skeletal muscle regeneration may also contribute to muscle wasting in cancer patients. However, there is little invitro or invivo data available, in either animals or in humans, regarding skeletal muscle regeneration in cancer wasting. The aim of the present review is to define the role of skeletal muscle regeneration in the muscle wasting of cancer patients and to determine possible therapeutic implications.

Bossola, M., Marzetti, E., Rosa, F., Pacelli, F., Skeletal muscle regeneration in cancer cachexia, <<CLINICAL AND EXPERIMENTAL PHARMACOLOGY & PHYSIOLOGY.>>, 2016; 43 (5): 522-527. [doi:10.1111/1440-1681.12559] [http://hdl.handle.net/10807/171366]

Skeletal muscle regeneration in cancer cachexia

Bossola, Maurizio;Marzetti, Emanuele;Rosa, Fausto;Pacelli, Fabio
2016

Abstract

Muscle wasting is the most important phenotypic and clinical feature of cancer cachexia, and the principal cause of impaired physical function, fatigue, and respiratory complications. Muscle loss has been attributed to a variable combination of reduced nutritional intake and an imbalance between anabolic and catabolic processes. It has been suggested that defective skeletal muscle regeneration may also contribute to muscle wasting in cancer patients. However, there is little invitro or invivo data available, in either animals or in humans, regarding skeletal muscle regeneration in cancer wasting. The aim of the present review is to define the role of skeletal muscle regeneration in the muscle wasting of cancer patients and to determine possible therapeutic implications.
2016
Inglese
Bossola, M., Marzetti, E., Rosa, F., Pacelli, F., Skeletal muscle regeneration in cancer cachexia, <<CLINICAL AND EXPERIMENTAL PHARMACOLOGY & PHYSIOLOGY.>>, 2016; 43 (5): 522-527. [doi:10.1111/1440-1681.12559] [http://hdl.handle.net/10807/171366]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/171366
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 25
social impact